Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-alpha 2a treatment
dc.creator | Mederacke, I. | en |
dc.creator | Yurdaydin, C. | en |
dc.creator | Dalekos, G. N. | en |
dc.creator | Bremer, B. | en |
dc.creator | Erhardt, A. | en |
dc.creator | Cakaloglu, Y. | en |
dc.creator | Yalcin, K. | en |
dc.creator | Gurel, S. | en |
dc.creator | Zeuzem, S. | en |
dc.creator | Zachou, K. | en |
dc.creator | Bozkaya, H. | en |
dc.creator | Dienes, H. P. | en |
dc.creator | Manns, M. P. | en |
dc.creator | Wedemeyer, H. | en |
dc.creator | Hep-Net Int Delta Hepatitis, Study | en |
dc.date.accessioned | 2015-11-23T10:39:16Z | |
dc.date.available | 2015-11-23T10:39:16Z | |
dc.date.issued | 2012 | |
dc.identifier | 10.3851/imp1926 | |
dc.identifier.issn | 1359-6535 | |
dc.identifier.uri | http://hdl.handle.net/11615/30863 | |
dc.description.abstract | Background: The role of anti-HDV immunoglobulin M (IgM) testing in patients receiving pegylated interferon-alpha therapy for hepatitis delta is unknown. We performed anti-HDV IgM testing in a well defined cohort of HDVinfected patients who were treated with pegylated interferon-alpha 2a plus adefovir, or either drug alone. Methods: Sera from 33 HDV-RNA-positive patients from the international HIDIT-1 trial were available for anti-HDV IgM testing (ETI-DELTA-IGMK-2 assay, DiaSorin, Saluggia, Italy) before therapy, at treatment weeks 24 and 48, and at 24 weeks after the end of treatment. Results: Anti-HDV IgM tested positive in 31 out of the 33 patients (94%) prior to treatment. HDV IgM levels correlated with histological inflammatory activity (r= 0.51, P<0.01) and were higher in patients with alanine aminotransferase and gamma-glutamyl transpeptidase levels above the median (P<0.05). Quantitative anti-HDV IgM values declined in patients responding to antiviral therapy, however anti-HDV IgM remained positive after treatment in the majority of virological responders. Conclusions: We suggest that anti-HDV IgM testing might give additional useful information to determine disease activity in hepatitis delta and to predict treatment response to antiviral therapy with type I interferons. However, determination of anti-HDV IgM can not substitute HDV RNA testing, which remains the primary virological marker for response to therapy. | en |
dc.source | Antiviral Therapy | en |
dc.source.uri | <Go to ISI>://WOS:000303987200006 | |
dc.subject | T-CELL RESPONSE | en |
dc.subject | VIRUS-INFECTION | en |
dc.subject | IGM ANTIBODIES | en |
dc.subject | I-INTERFERON | en |
dc.subject | PATTERNS | en |
dc.subject | THERAPY | en |
dc.subject | EUROPE | en |
dc.subject | SERUM | en |
dc.subject | RNA | en |
dc.subject | HBV | en |
dc.subject | Infectious Diseases | en |
dc.subject | Pharmacology & Pharmacy | en |
dc.subject | Virology | en |
dc.title | Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-alpha 2a treatment | en |
dc.type | journalArticle | en |
Αρχεία σε αυτό το τεκμήριο
Αρχεία | Μέγεθος | Τύπος | Προβολή |
---|---|---|---|
Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο. |